Detection of Early Lung Cancer among Military Personnel (DECAMP)
Abstract
The purpose of this work is to develop and validate molecular biomarkers found in blood, tissues, or other bodily fluids, which may be used for the early detection of lung cancer among military personnel and veterans. Over the course of the last year of this award, we have made significant progress towards enrollment in both clinical trials. We have recruited tilde92 percent of the 500 total subjects in the indeterminate pulmonary nodule study (Protocol 1), and tilde69 percent of the 800 total subjects in the longitudinal screening study (Protocol 2). The Leadership, Steering, Adjudication, Biostatistics, Imaging and Biomarker Committees continue to meet regularly. Most notably, significant progress has been made in collection and profiling of biospecimens from both cohorts, which will facilitate the validation of our cancer biomarkers. We have secured additional funding for the DECAMP consortium through July 2022, to ensure the completion of our enrollment goals and study aims. Lastly, we are finalizing discussions regarding dissemination and sharing of DECAMP data in the coming years.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2019
- Accession Number
- AD1094571
Entities
People
- Avrum E. Spira
- Ehab Billatos
- Elizabeth Moses
Organizations
- Boston University